China based microwave ablation (MWA) medical device developer, Baird Medical, has received approval from China’s National Medical Products Administration (NMPA) for its disposable MWA needle to treat benign thyroid nodules.
The MWA device operates similar to radiofrequency ablation (RFA) and uses a thin needle to distribute microwaves to the targeted area.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company insists the recent approval of its device will allow them to supply safe and advanced MWA products to treat thyroids while simultaneously continuing to offer minimally invasive treatments for patients with large thyroid cysts, nodular goiters, and patients who are unable to undergo surgery.
Commenting on the recent NMPA approval, Ms. Haimei Wu, CEO of Baird Medical said: “Our recent approval from China’s NMPA for our Class III disposable MWA needle is a testament to our unwavering commitment to scientific rigor, quality, and safety. We are proud of the strides we have made as a leading force in the development and provision of MWA devices.”
The company hopes the Class III certificate for its MWA needle will help streamline their sales process and give them an opportunity to expand its range of available specifications and models tailoring their sales strategy to an individual disease.
They also claim the certification will support a number of benefits for patients such as reduced costs compared to open surgery, fewer complications, reduced damage to surrounding tissues, reduced operation times, and the preservation of thyroid function post-surgery.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataOver the past two decades thyroid nodule ablation technology has become more popular compared to traditional surgical procedures with advantages like precise local anaesthesia and real-time ultrasound-guided tumour ablation.
In June 2023, Baird Medical signed a definitive business combination agreement to acquire ExcelFin combining the companies to operate as Baird Medical Investment Holdings following the closure of the deal.
